Migraine With or Without Aura Clinical Trial
Official title:
Randomized, Double-Blind, Study to Assess Low-Dose Naltrexone and Acetaminophen Combination in the Prevention of Episodic Migraine in Adults
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00792636 -
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
|
Phase 4 | |
Completed |
NCT00383162 -
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
|
Phase 3 | |
Completed |
NCT01986088 -
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
|
Phase 3 | |
Completed |
NCT02605174 -
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT01978496 -
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
|
Phase 3 | |
Completed |
NCT01989936 -
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
|
Phase 3 | |
Completed |
NCT06245902 -
An Acute Migraine Factorial Study
|
Phase 2 | |
Completed |
NCT03061734 -
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
|
Phase 2 | |
Completed |
NCT00382993 -
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
|
Phase 3 | |
Completed |
NCT01986270 -
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
|
Phase 3 |